E-viri
Recenzirano
Odprti dostop
-
Uchinami, Yusuke; Yasuda, Koichi; Kano, Satoshi; Otsuka, Manami; Hamada, Seijiro; Suzuki, Takayoshi; Tsushima, Nayuta; Takahashi, Shuhei; Fujita, Yoshihiro; Miyazaki, Tomohiko; Higaki, Hajime; Taguchi, Jun; Shimizu, Yasushi; Sakashita, Tomohiro; Homma, Akihiro; Aoyama, Hidefumi
Discover. Oncology, 25/1, Letnik: 15, Številka: 1Journal Article
Correction: Discover Oncology (2023) 14:226https://doi.org/10.1007/s12672-023-00844-7 After publication an error was found by the authors in the progression-free survival (PFS) analysis. Abstract Incorrect The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval CI: 64.8–90.7), 68.3% (95% CI 51.8–81.2), and 85.0% (95% CI 68.7–93.4), respectively. Correct The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval CI: 64.8–90.7), 58.9% (95% CI: 42.7–73.3), and 85.0% (95% CI: 68.7–93.4), respectively. Results Incorrect With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A). Correct With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A).
